| Year |
Citation |
Score |
| 2023 |
Reese SW, Eismann L, White C, Villada JA, Khaleel S, Ostrovnaya I, Vazquez-Rivera K, Carlo MI, Feldman D, Lee CH, Motzer R, Voss MH, Kotecha RR, Matulewicz RS, Goh A, et al. Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. Urologic Oncology. PMID 38135627 DOI: 10.1016/j.urolonc.2023.12.003 |
0.36 |
|
| 2023 |
Kotecha RR, Doshi SD, Knezevic A, Chaim J, Chen Y, Jacobi R, Zucker M, Reznik E, McHugh D, Shah NJ, Feld E, Aggen DH, Rafelson W, Xiao H, Carlo MI, ... ... Lee CH, et al. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology. PMID 37945488 DOI: 10.1016/j.euo.2023.10.017 |
0.423 |
|
| 2023 |
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, ... ... Lee CH, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet. Oncology. PMID 37451291 DOI: 10.1016/S1470-2045(23)00276-0 |
0.42 |
|
| 2023 |
Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, et al. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. European Urology Focus. PMID 36863962 DOI: 10.1016/j.euf.2023.02.008 |
0.374 |
|
| 2023 |
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, ... ... Lee CH, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. European Urology Oncology. PMID 36842942 DOI: 10.1016/j.euo.2023.01.012 |
0.374 |
|
| 2022 |
Fitzgerald KN, Motzer RJ, Lee CH. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nature Reviews. Urology. PMID 36369389 DOI: 10.1038/s41585-022-00666-2 |
0.389 |
|
| 2022 |
Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European Urology. PMID 36344318 DOI: 10.1016/j.eururo.2022.10.017 |
0.334 |
|
| 2022 |
Ged Y, Lee CH. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy. 22: 1049-1059. PMID 36154355 DOI: 10.1080/14737140.2022.2128336 |
0.42 |
|
| 2022 |
Tourigny DS, Zucker M, Kim M, Russo P, Coleman J, Lee CH, Carlo MI, Chen YB, Hakimi AA, Kotecha RR, Reznik E. Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Frontiers in Oncology. 12: 910147. PMID 35837094 DOI: 10.3389/fonc.2022.910147 |
0.374 |
|
| 2022 |
Kotecha RR, Gedvilaite E, Ptashkin R, Knezevic A, Murray S, Johnson I, Shapnik N, Feldman DR, Carlo MI, Shah NJ, Dunigan M, Huberman K, Benayed R, Zehir A, Berger MF, ... ... Lee CH, et al. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. Jco Precision Oncology. 6: e2200012. PMID 35797508 DOI: 10.1200/PO.22.00012 |
0.38 |
|
| 2022 |
Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, et al. Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35576438 DOI: 10.1158/1078-0432.CCR-22-0061 |
0.354 |
|
| 2022 |
Fitzgerald KN, Lee CH. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. Journal of the National Comprehensive Cancer Network : Jnccn. 1-9. PMID 35385828 DOI: 10.6004/jnccn.2022.7003 |
0.356 |
|
| 2022 |
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, et al. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101944. PMID 35298296 DOI: 10.1200/JCO.21.01944 |
0.374 |
|
| 2022 |
Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, et al. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus. PMID 35288096 DOI: 10.1016/j.euf.2021.12.002 |
0.371 |
|
| 2022 |
Carlo MI, Attalla K, Mazaheri Y, Gupta S, Yildirim O, Murray SJ, Coskey DT, Kotecha R, Lee CH, Feldman DR, Russo P, Patil S, Motzer RJ, Coleman JA, Durack JC, et al. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology. PMID 35183395 DOI: 10.1016/j.eururo.2022.01.043 |
0.311 |
|
| 2022 |
Tao JJ, Wei G, Patel R, Fagan P, Hao X, Bridge JA, Arcila ME, Al-Ahmadie H, Lee CH, Li G, Drilon A. Fusions in Renal Cell Carcinoma: Response to Entrectinib. Jco Precision Oncology. 2: 1-8. PMID 35135161 DOI: 10.1200/PO.18.00185 |
0.376 |
|
| 2021 |
Kotecha RR, Hsu DJ, Lee CH, Patil S, Voss MH. In silico modeling of combination systemic therapy for advanced renal cell carcinoma. Journal For Immunotherapy of Cancer. 9. PMID 34952852 DOI: 10.1136/jitc-2021-004059 |
0.364 |
|
| 2021 |
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, et al. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34759043 DOI: 10.1158/1078-0432.CCR-21-2283 |
0.32 |
|
| 2021 |
Truong H, Sheikh R, Kotecha R, Kemel Y, Reisz PA, Lenis AT, Mehta NN, Khurram A, Joseph V, Mandelker D, Latham A, Ceyhan-Birsoy O, Ladanyi M, Shah NJ, Walsh MF, ... ... Lee CH, et al. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology. PMID 34654685 DOI: 10.1016/j.euo.2021.09.005 |
0.362 |
|
| 2021 |
George DJ, Lee CH, Heng D. New approaches to first-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology. 13: 17588359211034708. PMID 34527080 DOI: 10.1177/17588359211034708 |
0.342 |
|
| 2021 |
Lee CH, Wan Y, Smith A, Xie R, Motzer RJ. Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. European Urology Open Science. 31: 1-9. PMID 34467233 DOI: 10.1016/j.euros.2021.06.008 |
0.316 |
|
| 2021 |
Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee CH, Carlo MI, Durack JC, Solomon SB, Reuter V, Russo P, Chan TA, et al. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34261695 DOI: 10.1158/1078-0432.CCR-20-4058 |
0.359 |
|
| 2021 |
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet. Oncology. PMID 34143969 DOI: 10.1016/S1470-2045(21)00241-2 |
0.405 |
|
| 2021 |
Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, Vuong L, Lee M, Weiss K, Hoen D, Morris L, Reznik E, Murray S, Kotecha R, Voss MH, et al. High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab. Molecular Cancer Research : McR. PMID 34039647 DOI: 10.1158/1541-7786.MCR-21-0053 |
0.351 |
|
| 2021 |
Gleeson JP, Nikolovski I, DiNatale RG, Zucker M, Knezevic A, Patil S, Ged Y, Kotecha RR, Shapnik N, Murray S, Russo P, Coleman J, Lee CH, Stadler ZK, Hakimi AA, et al. Comprehensive Molecular Characterization and Response to Therapy in FH-Deficient Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33658299 DOI: 10.1158/1078-0432.CCR-20-4367 |
0.394 |
|
| 2020 |
Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Jungbluth AA, Al-Ahmadie H, Ostrovnaya I, Chaim J, Bajorin DF, Rosenberg JE, et al. A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. Cancer Medicine. PMID 33382520 DOI: 10.1002/cam4.3699 |
0.304 |
|
| 2020 |
Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funahashi Y, Voss MH. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. British Journal of Cancer. PMID 33024271 DOI: 10.1038/s41416-020-01092-0 |
0.359 |
|
| 2020 |
Feldman DR, Ged Y, Lee CH, Knezevic A, Molina AM, Chen YB, Chaim J, Coskey DT, Murray S, Tickoo SK, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, et al. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. PMID 32975815 DOI: 10.1002/cncr.33148 |
0.408 |
|
| 2020 |
Ged Y, Gupta R, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Voss MH, Feldman DR, Akin O, Patil S, Motzer RJ, Rini BI, Lee CH. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. Bmc Urology. 20: 84. PMID 32616076 DOI: 10.1186/S12894-020-00647-W |
0.448 |
|
| 2020 |
Ged Y, Chaim JL, DiNatale RG, Knezevic A, Kotecha RR, Carlo MI, Lee CH, Foster A, Feldman DR, Teo MY, Iyer G, Chan T, Patil S, Motzer RJ, Hakimi AA, et al. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. Journal For Immunotherapy of Cancer. 8. PMID 32571992 DOI: 10.1136/Jitc-2019-000230 |
0.409 |
|
| 2020 |
Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901598. PMID 31961766 DOI: 10.1200/Jco.19.01598 |
0.378 |
|
| 2020 |
Attalla K, Duzgol C, McLaughlin L, Flynn J, Ostrovnaya I, DiNatale RG, Silagy AW, Coleman J, Lee C, Carlo MI, Voss MH, Russo P, Bilsky M, Hakimi AA, Moss N. The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. Journal of Clinical Oncology. 38: 742-742. DOI: 10.1200/Jco.2020.38.6_Suppl.742 |
0.433 |
|
| 2020 |
Lee C, DiNatale RG, Chowell D, Krishna C, Makarov V, Shapnik N, Murray SJ, Carlo MI, Voss MH, Feldman DR, Hakimi AA, Adachi Y, Minoshima Y, Matsui J, Funahashi Y, et al. Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 38: 733-733. DOI: 10.1200/Jco.2020.38.6_Suppl.733 |
0.462 |
|
| 2020 |
Gleeson JP, Nikolovski I, Kotecha R, Ged Y, Shapnik N, Knezevic A, Feldman DR, Lee C, Voss MH, Chen Y, Motzer RJ, Carlo MI. Response to systemic therapy in patients with metastatic fumarate hydratase (FH) deficient renal cell carcinoma (RCC). Journal of Clinical Oncology. 38: 686-686. DOI: 10.1200/Jco.2020.38.6_Suppl.686 |
0.473 |
|
| 2020 |
Attalla K, DiNatale RG, Reznik E, Fong C, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee C, Carlo MI, Russo P, Chan TA, Motzer RJ, Schultz ND, Voss MH, et al. Prevalence and landscape of actionable genomic alterations in renal cell carcinoma. Journal of Clinical Oncology. 38: 616-616. DOI: 10.1200/Jco.2020.38.6_Suppl.616 |
0.442 |
|
| 2020 |
Sarfaty M, Teo MY, Al-Ahmadie H, Funt SA, Lee C, Aggen DH, Solit DB, Ratna N, Regazzi AM, Hechtman JF, Zehir A, Rosenberg JE, Bajorin DF, Iyer G. Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy. Journal of Clinical Oncology. 38: 566-566. DOI: 10.1200/Jco.2020.38.6_Suppl.566 |
0.342 |
|
| 2020 |
Sarfaty M, Ostrovnaya I, Teo MY, Iyer G, Lee C, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Al-Ahmadie H, Chaim J, Bajorin DF, Rosenberg JE, Funt SA. A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract. Journal of Clinical Oncology. 38: 514-514. DOI: 10.1200/Jco.2020.38.6_Suppl.514 |
0.411 |
|
| 2020 |
Kotecha R, Lee C, Knezevic A, Shah NJ, Carlo MI, Feldman DR, Patil S, Motzer RJ, Voss MH. Impact of treatment line on outcomes with salvage ipilimumab + nivolumab in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E17092 |
0.42 |
|
| 2020 |
Sarfaty M, Teo MY, Funt SA, Lee C, Aggen DH, Ratna N, Regazzi AM, Al-Ahmadie H, Brannon AR, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy. Journal of Clinical Oncology. 38: e17034-e17034. DOI: 10.1200/Jco.2020.38.15_Suppl.E17034 |
0.324 |
|
| 2020 |
Lee C, Wan Y, Smith AD, Xie R, Motzer RJ. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 38: 5067-5067. DOI: 10.1200/Jco.2020.38.15_Suppl.5067 |
0.42 |
|
| 2020 |
Teo MY, Whiting K, Mota JM, Li H, Regazzi AM, Solit DB, Aggen DH, Lee C, Funt SA, Bajorin DF, Ostrovnaya I, Iyer G, Rosenberg JE. Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 38: 5050-5050. DOI: 10.1200/Jco.2020.38.15_Suppl.5050 |
0.333 |
|
| 2020 |
Lee C, Shah AY, Hsieh JJ, Rao A, Pinto A, Bilen MA, Cohn AL, Di Simone C, Shaffer DR, Girones Sarrio R, Gunnestad Ribe S, Wu J, Schmidt EV, Perini RF, Kubiak P, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Journal of Clinical Oncology. 38: 5008-5008. DOI: 10.1200/Jco.2020.38.15_Suppl.5008 |
0.377 |
|
| 2020 |
Choueiri TK, Kluger HM, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee C, Hotte SJ, Miller WH, Saggi SS, et al. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology. 38: 5007-5007. DOI: 10.1200/Jco.2020.38.15_Suppl.5007 |
0.477 |
|
| 2020 |
Attalla* K, DiNatale RG, Reznik E, Fong C, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee C, Carlo MI, Russo P, Chan TA, Schultz ND, Voss MH, Hakimi AA. PD39-05 PREVALENCE AND LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS IN RENAL CELL CARCINOMA The Journal of Urology. 203: e810. DOI: 10.1097/Ju.0000000000000918.05 |
0.424 |
|
| 2020 |
Attalla K, Duzgol C, McLaughlin L, Flynn J, Ostrovnaya I, DiNatale RG, Silagy AW, Coleman J, Lee C, Carlo MI, Voss MH, Russo P, Bilsky M, Hakimi AA, Moss N. Mp14-15 The Spinal Distribution Of Metastatic Renal Cell Carcinoma: Support For Locoregional Rather Than Arterial Hematogenous Mode Of Early Bony Dissemination The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000839.015 |
0.393 |
|
| 2019 |
Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A, Coskey DT, Hyman DM, Ladanyi M, Chen YB, Robson M, Hakimi AA, Lee CH, Feldman DR, Gao J, et al. Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. Jco Precision Oncology. 3. PMID 32914011 DOI: 10.1200/PO.18.00372 |
0.442 |
|
| 2019 |
Gleeson JP, Motzer RJ, Lee CH. The current role for adjuvant and neoadjuvant therapy in renal cell cancer. Current Opinion in Urology. PMID 31348025 DOI: 10.1097/Mou.0000000000000666 |
0.464 |
|
| 2019 |
Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Voss MH, Motzer RJ. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 31151928 DOI: 10.1016/J.Clgc.2019.04.006 |
0.443 |
|
| 2019 |
Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 31036466 DOI: 10.1016/J.Clgc.2019.03.018 |
0.479 |
|
| 2019 |
Hakimi AA, Ged Y, Flynn J, Hoen DR, Di Natale RG, Blum KA, Makarov V, Kuo F, Carlo MI, Lee C, Voss MH, Ostrovnaya I, Chan TA, Motzer RJ. The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB). Journal of Clinical Oncology. 37: 666-666. DOI: 10.1200/Jco.2019.37.7_Suppl.666 |
0.381 |
|
| 2019 |
Lee C, Natale RGD, Chowell D, Makarov V, Redzematovic A, Murray SJ, Carlo MI, Voss MH, Feldman DR, Motzer RJ, Chan TA, Hakimi AA. Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 37: 641-641. DOI: 10.1200/Jco.2019.37.7_Suppl.641 |
0.516 |
|
| 2019 |
Ged Y, Chaim J, Knezevic A, Carlo MI, Foster A, Feldman DR, Teo MY, Riaz N, Lee C, Patil S, Chan TA, Hakimi AA, Motzer RJ, Voss MH. Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts). Journal of Clinical Oncology. 37: 551-551. DOI: 10.1200/Jco.2019.37.7_Suppl.551 |
0.431 |
|
| 2019 |
Mota JMSC, Teo MY, Li H, Balar AV, Milowsky MI, Funt SA, Lee C, Regazzi AM, Berger MF, Solit DB, Bajorin DF, Rosenberg JE, Iyer G. Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity? Journal of Clinical Oncology. 37: 459-459. DOI: 10.1200/Jco.2019.37.7_Suppl.459 |
0.319 |
|
| 2019 |
Ged Y, Lee C, Sanchez A, Duzgol C, Chaim J, Carlo MI, Foster A, Akin O, Feldman DR, Hakimi AA, Patil S, Motzer RJ, Furberg H, Voss MH. Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16103 |
0.408 |
|
| 2019 |
Mota JM, Teo MY, Whiting K, Ostrovnaya I, Li H, Lee C, Funt SA, Callahan MK, Iyer G, Bajorin DF, Rosenberg JE. Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16035 |
0.315 |
|
| 2019 |
Ged Y, Gupta R, Duzgol C, Shapnik N, Redzematovic A, Kotecha R, Voss MH, Feldman DR, Akin O, Patil S, Motzer RJ, Rini BI, Lee C. Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF). Journal of Clinical Oncology. 37: 4576-4576. DOI: 10.1200/Jco.2019.37.15_Suppl.4576 |
0.43 |
|
| 2019 |
Funt SA, Jatwani K, Makris M, Regazzi AM, Lee C, Teo MY, McHugh DJ, McCoy AS, Hettich G, Wong P, Abu-Akeel M, Wolchok JD, Merghoub T, Al-Ahmadie H, Ostrovnaya I, et al. A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). Journal of Clinical Oncology. 37: 4559-4559. DOI: 10.1200/Jco.2019.37.15_Suppl.4559 |
0.314 |
|
| 2019 |
DiNatale R, Lee C, Chowell D, Makarov V, Redzematovic A, Murray S, Carlo M, Voss M, Coleman J, Russo P, Motzer R, Chan T, Hakimi A. Mp25-10 Genomic Biomarkers Of Response To Nivolumab/Ipilimumab And Nivolumab Monotherapy In 108 Patients With Metastatic Renal Cell Carcinoma The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555655.66085.F9 |
0.511 |
|
| 2018 |
Lee CH, Motzer RJ. Combination therapy for advanced and metastatic kidney cancer. Nature Reviews. Urology. PMID 30538301 DOI: 10.1038/S41585-018-0133-7 |
0.361 |
|
| 2018 |
Lee CH, Motzer R. Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. British Journal of Cancer. PMID 30327569 DOI: 10.1038/S41416-018-0175-X |
0.477 |
|
| 2018 |
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer. PMID 30287223 DOI: 10.1016/J.Clgc.2018.09.005 |
0.399 |
|
| 2018 |
Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, ... ... Lee CH, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. Jama Oncology. PMID 29978187 DOI: 10.1001/Jamaoncol.2018.1986 |
0.451 |
|
| 2018 |
Ged Y, Knezevic A, Chen Y, Redzematovic A, Carlo MI, Lee C, Feldman DR, Patil S, Motzer RJ, Voss MH. Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF). Journal of Clinical Oncology. 36: 678-678. DOI: 10.1200/Jco.2018.36.6_Suppl.678 |
0.367 |
|
| 2018 |
Feldman DR, Lee C, Molina AM, Knezevic A, Chen Y, Chaim J, Coskey DT, Ged Y, Tickoo S, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, Carlo MI, et al. Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial. Journal of Clinical Oncology. 36: 627-627. DOI: 10.1200/Jco.2018.36.6_Suppl.627 |
0.387 |
|
| 2018 |
Ged Y, Knezevic A, Chen Y, Redzematovic A, Carlo MI, Lee C, Feldman DR, Patil S, Motzer RJ, Voss MH. Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant. Journal of Clinical Oncology. 36: 4577-4577. DOI: 10.1200/Jco.2018.36.15_Suppl.4577 |
0.475 |
|
| 2018 |
Lee C, Makker V, Rasco DW, Taylor MH, Stepan DE, Shumaker RC, Schmidt EV, Guo M, Dutcus CE, Motzer RJ. Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results. Journal of Clinical Oncology. 36: 4560-4560. DOI: 10.1200/Jco.2018.36.15_Suppl.4560 |
0.412 |
|
| 2017 |
Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, ... ... Lee CH, et al. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus. PMID 29066084 DOI: 10.1016/J.Euf.2017.09.016 |
0.477 |
|
| 2017 |
Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical Genitourinary Cancer. PMID 28558987 DOI: 10.1016/J.Clgc.2017.04.012 |
0.463 |
|
| 2017 |
Lee CH, Motzer RJ. Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer. Nature Reviews. Nephrology. 13: 69-70. PMID 28100904 DOI: 10.1038/Nrneph.2016.194 |
0.386 |
|
| 2017 |
Carlo MI, Khan N, Chen Y, Hsieh J, Hakimi AA, Lee C, Feldman DR, Motzer RJ, Voss MH. The genomic landscape of metastatic non-clear cell renal cell carcinoma. Journal of Clinical Oncology. 35: 474-474. DOI: 10.1200/Jco.2017.35.6_Suppl.474 |
0.448 |
|
| 2017 |
Carlo MI, Mukherjee S, Kemel Y, Zhang L, Mandelker D, Vijai J, Coskey DT, Pradhan N, Hyman DM, Hakimi AA, Coleman J, Lee C, Feldman DR, Voss MH, Offit K, et al. Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology. 35: 4524-4524. DOI: 10.1200/Jco.2017.35.15_Suppl.4524 |
0.378 |
|
| 2016 |
Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, ... ... Lee CH, et al. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus. PMID 28753786 DOI: 10.1016/J.Euf.2016.08.005 |
0.363 |
|
| 2016 |
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, et al. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601542 DOI: 10.1200/Jco.2016.67.9084 |
0.523 |
|
| 2016 |
Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. The Journal of Clinical Investigation. PMID 27482884 DOI: 10.1172/Jci86120 |
0.351 |
|
| 2016 |
Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ, H Voss M. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The Oncologist. PMID 27286790 DOI: 10.1634/Theoncologist.2016-0145 |
0.495 |
|
| 2016 |
Lee CH, Motzer RJ. Immune Checkpoint Therapy in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass.). 22: 92-5. PMID 27111903 DOI: 10.1097/Ppo.0000000000000177 |
0.389 |
|
| 2016 |
Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. British Journal of Cancer. PMID 26908330 DOI: 10.1038/Bjc.2016.21 |
0.478 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... Lee CH, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.623 |
|
| 2016 |
Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 29: 104-116. PMID 26766592 DOI: 10.1016/J.Ccell.2015.12.004 |
0.385 |
|
| 2016 |
Gowrishankar B, Janakiraman M, Lee C, Thodima VJ, Molina AM, Patel PH, Gold TM, Motzer RJ, Chaganti RSK, Kamalakaran S, Houldsworth J. Metastasis-associated mutations in clear cell renal cell carcinoma. Journal of Clinical Oncology. 34: 600-600. DOI: 10.1200/Jco.2016.34.2_Suppl.600 |
0.471 |
|
| 2016 |
Lee C, Motzer RJ, Hoetker A, Akin O, Molina AM, Gold TM, Patil S, Janakiraman M, Gowrishankar B, Houldsworth J. Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16109 |
0.508 |
|
| 2016 |
Lee C, Wei E, Lee W, Chen Y, Mano R, Hakimi AA, Dong Y, Redzematovic A, Cross JR, Tickoo S, Srinivasan R, Oschwald D, Reuter VE, Dunphy M, Cheng E, et al. Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16102 |
0.449 |
|
| 2016 |
Carlo MI, Chen Y, Chaim J, Coskey DT, Woo K, Hsieh J, Voss MH, Feldman DR, Motzer RJ, Lee C. Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes. Journal of Clinical Oncology. 34: 4556-4556. DOI: 10.1200/Jco.2016.34.15_Suppl.4556 |
0.471 |
|
| 2015 |
Lee CH, Hötker AM, Voss MH, Feldman DR, Woo KM, Patil S, Coskey DT, Akin O, Hsieh JJ, Motzer RJ. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical Genitourinary Cancer. PMID 26404107 DOI: 10.1016/J.Clgc.2015.07.010 |
0.432 |
|
| 2015 |
Lee CH, Motzer RJ. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. Urologic Oncology. 33: 275-279. PMID 25465298 DOI: 10.1016/J.Urolonc.2014.10.012 |
0.421 |
|
| 2015 |
Lee C, Hoetker AM, Voss MH, Feldman DR, Woo K, Patil S, Coskey DT, Akin O, Hsieh J, Motzer RJ. Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs. Journal of Clinical Oncology. 33: 468-468. DOI: 10.1200/Jco.2015.33.7_Suppl.468 |
0.404 |
|
| 2015 |
Lee C, Motzer R, Hoetker A, Akin O, Molina AM, Gold TM, Patil S, Gowrishankar B, Houldsworth J. Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 33: 4552-4552. DOI: 10.1200/Jco.2015.33.15_Suppl.4552 |
0.496 |
|
| 2014 |
Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treatment Reviews. 40: 533-47. PMID 24398141 DOI: 10.1016/J.Ctrv.2013.11.008 |
0.44 |
|
| 2014 |
Lee CH, Motzer RJ. From molecular understanding to clinical advances. Nature Reviews. Urology. 11: 77-9. PMID 24366347 DOI: 10.1038/Nrurol.2013.307 |
0.446 |
|
| 2014 |
Lee C, Voss MH, Mano R, Motzer RJ, Hsieh J. Src pathway activation in RCC and the correlation with grade and survival and the development of a rational new target in RCC. Journal of Clinical Oncology. 32: 453-453. DOI: 10.1200/Jco.2014.32.4_Suppl.453 |
0.394 |
|
| 2014 |
Hakimi AA, Tickoo SK, Xu J, Lee C, Mano R, Chen Y, Stirdivant S, Neri B, Wolfert R, Fine SW, Al-Ahmadie H, Gopalan A, Russo P, Reuter VE, Hsieh JJ. MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC) Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1062 |
0.465 |
|
| 2013 |
Lee CH, Cross JR, Li Z, Chen Y, Neri B, Reuter VE, Motzer RJ, Russo P, Hsieh J. Global metabolic profiling of clear cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 379. PMID 28136900 DOI: 10.1200/Jco.2013.31.6_Suppl.379 |
0.488 |
|
| 2013 |
Hakimi AA, Lee C, Cross JR, Li Z, Chen Y, Neri B, Reuter VE, Motzer R, Russo P, Hsieh JJ. 469 GLOBAL METABOLIC PROFILING OF CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1860 |
0.461 |
|
| 2007 |
Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP, Guan KL. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. The Embo Journal. 26: 4812-23. PMID 17962806 DOI: 10.1038/Sj.Emboj.7601900 |
0.421 |
|
| 2007 |
Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annual Review of Pharmacology and Toxicology. 47: 443-67. PMID 16968213 DOI: 10.1146/annurev.pharmtox.47.120505.105359 |
0.436 |
|
| Show low-probability matches. |